PolyPid Ltd.NASDAQ: PYPD

PolyPid to Report Second Quarter 2026 Financial Results and Operational Highlights on August 12, 2026

· Issued by PolyPid Ltd. via GlobeNewswire

Summary by 6ix AI

PolyPid Ltd., a biopharmaceutical company that develops long-acting, controlled-release drugs designed to deliver therapy at the site of care, will report its second quarter 2026 financial results and operational highlights before the US markets open on Wednesday, August 12, 2026.

Key details

  • PolyPid will host a conference call and webcast at 8:30 AM Eastern Time on Wednesday, August 12, 2026 to discuss the results and give an update on business operations.
  • PolyPid suggests registering at least 5 minutes before the call starts, and recommends the webcast for those not planning to ask management a question.

6ix AI wrote this summary from the release below and checked it against the release.

PETACH TIKVA, Israel, July 30, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), an innovative biopharmaceutical company dedicated to improving patient outcomes by elevating treatment effectiveness, right where care begins, today announced that it will report its second quarter 2026 financial results and operational highlights before the open of the U.S. financial markets on Wednesday, August 12, 2026. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations.

To ensure you are connected prior to the beginning of the call, PolyPid suggests registering a minimum of 5 minutes before the start of the call. For those not planning to ask a question of management, the Company recommends listening via the webcast.

Conference Call Dial-In & Webcast Information:

Date:

Wednesday, August 12, 2026

Time:

8:30 AM Eastern Time

Conference Call:

Webcast:

About PolyPid
PolyPid Ltd. (Nasdaq: PYPD) is an innovative biopharmaceutical company dedicated to elevating treatment effectiveness, right where care begins. The Company develops long-acting, controlled-release drugs designed to deliver therapy precisely at the site of care, addressing critical unmet medical needs across a wide and diverse pipeline spanning surgical care, metabolic diseases, and beyond. PolyPid's lead product, D-PLEX₁₀₀, successfully met its primary and all key secondary endpoints in the landmark Phase 3 SHIELD II trial for the prevention of surgical site infections. Guided by a commitment to precision and innovation, PolyPid is redefining how therapies perform and raise the standard of patient care. For additional Company information, please visit http://www.polypid.com and follow us on Twitter (X) and LinkedIn.

Company Contact:
PolyPid Ltd.
Ori Warshavsky
908-858-5995
[email protected]

Investor Relations Contact:
Arx Investor Relations
North American Equities Desk
[email protected]

PolyPid Ltd. on 6ix

Story so far

Earlier from PolyPid

Later from PolyPid

All PolyPid news releases